May 17, 2023
CASI Pharmaceuticals Announces First Quarter 2023 Financial ResultsApril 26, 2023
CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022April 26, 2023
CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTSMarch 21, 2023
CASI Pharmaceuticals Completes Redomiciliation MergerJanuary 06, 2023
CASI Pharmaceuticals And Cleave Therapeutics Announce Clinical Trial Application Approval For CB-5339 In Patients With Multiple Myeloma In ChinaDecember 15, 2022
CASI Pharmaceuticals’ Partner Juventas Announces New Drug Application For CNCT19 Accepted By China National Medical Products AdministrationNovember 14, 2022
CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTSSeptember 23, 2022
CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEETSeptember 09, 2022
CASI Pharmaceuticals And BioInvent Announce Dosing Of First Patient In BI-1206 Phase 1 Clinical Trial For The Treatment Of Relapsed/Refractory Non-Hodgkin’s Lymphoma In ChinaAugust 12, 2022
CASI Pharmaceuticals Announces Second Quarter 2022 Financial ResultsJuly 08, 2022
CASI Pharmaceuticals Announces Its Partner, Precision Autoimmune Therapeutics Co., Ltd Has Completed First-Round Financing Of $21 MillionMay 26, 2022
CASI Pharmaceuticals Announces Reverse Stock SplitMay 24, 2022
CASI Pharmaceuticals Enters Into Sublicense Agreement With Tianshi Pharmaceuticals For Anti-CD38 Monoclonal Antibody (MAB) CID-103 In Autoimmune FieldMay 12, 2022
CASI Pharmaceuticals Announces First Quarter 2022 Financial ResultsMay 02, 2022
CASI Pharmaceuticals to report first quarter 2022 financial results and host conference call May 12, 2022April 01, 2022
CASI Pharmaceuticals Statement On Status Under Holding Foreign Companies Accountable ActMarch 28, 2022
CASI Pharmaceuticals Announces Full-Year 2021 Financial Results And Fourth Quarter 2021 Evomela® RevenueMarch 23, 2022
CASI Pharmaceuticals To Report Fourth Quarter And Year End 2021 Financial Results And Host Conference Call March 28, 2022March 04, 2022
CASI Pharmaceuticals Announces Renewal Of Exclusive Distribution Agreement For Evomela® In ChinaFebruary 16, 2022
CASI Pharmaceuticals Announces Preliminary Fourth Quarter And Full-Year 2021 Revenues And Provides Business Updates
